Summary
Background
Uveitis is a known ocular manifestation in individuals who have survived Ebola virus disease (EVD). However, whether Ebola virus (EBOV; Orthoebolavirus zairense) persistence in vitreous fluid contributes to long-term sequelae of uveitis in EVD survivors remains unclear. We aimed to characterise the clinical findings and molecular and immunological findings in vitreous fluid from EVD survivors undergoing vitreoretinal surgery.
Methods
This cross-sectional study recruited EVD survivors (cohort 1), household close contacts of EVD survivors (cohort 2), and non-EVD patients with uveitis (cohort 3) from the Sierra Leone Ministry of Health’s Department of Ophthalmology or from the ongoing Sierra Leone Ministry of Health and the Lowell and Ruth Gess Eye Hospital Ebola Survivor Study (SMILE Study). EVD survivor status was based on an Ebola treatment unit certificate and confirmation in the Sierra Leone Association of Ebola Survivors registry, as well as an anti-EBOV assay. Close contacts of EVD survivors were individuals who lived in the same household as patients with EVD during the acute stage of the disease. Non-EVD patients with uveitis were individuals with vitreoretinal disease indications who were anticipated to benefit from surgical intervention. All patients had a comprehensive ophthalmic examination and pars plana vitrectomy with collection of vitreous fluid. These samples were investigated for molecular detection of EBOV RNA via quantitative RT-PCR (qRT-PCR) and evaluation of Goldmann–Witmer coefficients (GWCs) to identify intraocular production of EBOV-binding antibodies. Statistical analyses were performed to compare basic ophthalmic variables, demographic data, and GWC between the three groups.
Findings
From Jan 1, 2023, to Jan 1, 2024, a total of 25 patients (cohort 1 n=10, cohort 2 n=5, cohort 3 n=10) were enrolled. 13 (52%) patients were female, and median age was 39 years (IQR 34·0–53·5). The median time from EVD symptom onset to surgery was 108·5 months (IQR 103·8–110·8) in cohort 1, and the median time from close contact with a patient with EVD to surgery was 106·0 months (IQR 103·0–106·0) in cohort 2. EBOV RNA was detected by qRT-PCR in the vitreous fluid of two (20%) of ten EVD survivors. GWCs for EBOV glycoprotein IgG were significantly elevated (median 3·59, IQR 0·93–12·53, p<0·005 for between-group comparisons) in EVD survivors compared with those in close contacts (median 0, IQR 0–2·2) and patients with uveitis (median 0, IQR 0–0·62).
Interpretation
The detection of virus-specific immune responses and viral RNA at a median of 9 years after EVD diagnosis suggests long-term EBOV RNA persistence in the vitreous fluid of EVD survivors with vitreoretinal disease.
Funding
National Eye Institute of the National Institutes of Health, National Cancer Institute, National Institutes of Health, and Australian National Health and Medical Research Council.
Source: The Lancet Microbe, https://doi.org/10.1016/j.lanmic.2026.101547
____

No comments:
Post a Comment